Trade

with

Tesaro Inc
(NASDAQ: TSRO)
AdChoices
26.08
-0.32
-1.21%
After Hours :
26.08
0.00
0.00%

Open

26.22

Previous Close

26.40

Volume (Avg)

291.54k (293.84k)

Day's Range

25.97-27.10

52Wk Range

22.15-41.25

Market Cap.

940.01M

Dividend Rate ( Yield )

-

Beta

0.57

Shares Outstanding

36.04M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -92.36M

    • Market Cap.

    • 940.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.57

    • Forward P/E

    • -5.73

    • Price/Sales

    • -

    • Price/Book Value

    • 6.85

    • Price/Cash flow

    • -8.57

      • EBITDA

      • -92.27M

      • Return on Capital %

      • -82.32

      • Return on Equity %

      • -90.65

      • Return on Assets %

      • -82.32

      • Book Value/Share

      • 3.80

      • Shares Outstanding

      • 36.04M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 70.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -4.49

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 8.10

              • 2.92

              • Quick Ratio

              • 7.95

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.14

              • 2.21

              • Book Value/Share

              • 3.80

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.30

                • 277.78

                • P/E Ratio 5-Year High

                • -12.72

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.71

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.35

                • Price/Book Value

                • 6.76

                • 8.50

                • Price/Cash Flow Ratio

                • -8.57

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -90.65

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -82.32

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -90.65

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -92.44M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -8.57
                  Ownership

                  Institutional Ownership

                  98.24%

                  Top 10 Institutions

                  71.79%

                  Mutual Fund Ownership

                  39.10%

                  Float

                  56.24%

                  5% / Insider Ownership

                  5.24%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,072,115

                  • 0.00

                  • 2.97

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,065,038

                  • 7.13

                  • 2.96

                  • Vanguard Explorer Fund

                  •  

                    839,708

                  • 39.95

                  • 2.33

                  • Bb Biotech AG

                  •  

                    704,582

                  • 0.00

                  • 1.95

                  • Goldman Sachs Small Cap Value

                  •  

                    606,525

                  • 56.08

                  • 1.68

                  • SPDR® S&P Biotech ETF

                  •  

                    598,427

                  • 0.00

                  • 1.63

                  • Franklin Biotechnology Discovery

                  •  

                    546,200

                  • 53.90

                  • 1.52

                  • T. Rowe Price New Horizons Fund

                  •  

                    507,781

                  • 34.06

                  • 1.41

                  • Vanguard Total Stock Mkt Idx

                  •  

                    325,457

                  • 0.00

                  • 0.90

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • NEA Management Company, LLC

                  •  

                    9,854,255

                  • 0.00%

                  • 27.34

                  • Wellington Management Company, LLP

                  •  

                    4,359,831

                  • +17.60%

                  • 12.10

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,474,339

                  • +39.62%

                  • 6.87

                  • InterWest Management Partners X LLC

                  •  

                    2,471,701

                  • -19.53%

                  • 7.58

                  • Healthcor Management, L.p.

                  •  

                    1,475,000

                  • +5.36%

                  • 4.09

                  • AllianceBernstein LP

                  •  

                    1,377,670

                  • +7.86%

                  • 3.82

                  • Fidelity Management and Research Company

                  •  

                    1,225,894

                  • -7.49%

                  • 3.40

                  • Vanguard Group, Inc.

                  •  

                    828,226

                  • +1.64%

                  • 2.30

                  • Franklin Advisers, Inc.

                  •  

                    800,300

                  • 0.00%

                  • 2.22

                  • State Street Corp

                  •  

                    746,747

                  • +3.72%

                  • 2.07

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  -

                  TESARO, Inc. was incorporated in the State of Delaware on March 26, 2010. The Company is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. It has in-licensed and are currently developi...moreng three product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase 3 "oral formulation" and Phase 1 "intravenous, or IV, formulation" clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV. Niraparib, formerly known as MK-4827, is an orally active and potent poly "ADP-ribose" polymerase, or PARP, inhibitor. TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase, or ALK, and tro...morepomyosin-related kinase, or TRK, currently in a Phase 1/2a dose escalation clinical trial in cancer patients. The Company may face competition from pharmaceutical and biotechnology companies, including specialty pharmaceutical companies and generic drug companies, academic institutions, government agencies and research institutions, and others. The Company operates in the United States and is subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies.lessless

                  Key People

                  Leon O. Moulder,Jr

                  CEO/DirectorCo-Founder

                  David Mott

                  Chairman of the Board/Director

                  Dr. Mary Lynne Hedley,PhD

                  Chief Scientific Officer/Co-Founder/COO/Director/President

                  Mr. Timothy R. Pearson

                  CFO/Executive VP

                  Mr. Edward (Ted) C. English

                  Chief Accounting Officer/Vice President, Divisional

                  • Tesaro Inc

                  • 1000 Winter Street

                  • Waltham, MA 02451

                  • USA.Map

                  • Phone: +1 339 970-0900

                  • Fax: -

                  • tesarobio.com

                  Incorporated

                  2010

                  Employees

                  62

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: